Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2020

01-12-2020 | Hypoglycemia | Research

Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study

Authors: Akemi Tokutsu, Yosuke Okada, Keiichi Torimoto, Yoshiya Tanaka

Published in: Diabetology & Metabolic Syndrome | Issue 1/2020

Login to get access

Abstract

Background

Treatment indexes using continuous glucose monitoring (CGM) have become standardized internationally, and the use of ambulatory glucose profile (AGP) is currently recommended. However, the relationship between AGP indexes and standardized CGM metrics has not been investigated. Using flash glucose monitoring (FGM), this retrospective study served to evaluate the association of the inter-quartile range (IQR) of AGP with standardized CGM metrics.

Methods

The study subjects were 30 patients with type 2 diabetes mellitus (T2DM) and 23 non-diabetic patients (control group). We evaluated average IQR (AIQR) and standardized CGM metrics. The primary endpoint was the relationship between AIQR and Time in range (TIR) in a 24-h period.

Results

In the T2DM group, the AIQR was notably high and correlated negatively with TIR, and positively with Time above range, average interstitial glucose level, standard deviation of interstitial glucose, coefficient of variation of interstitial glucose, and mean of daily difference in blood glucose (MODD). For the T2DM group, the AIQR was notably lower in patients who achieved TIR > 70%, compared to those who did not. The AIQR cutoff value, as determined by ROC analysis, was 28.3 mg/dl for those who achieved TIR > 70%. No association was detected between the presence of hypoglycemia and AIQR.

Conclusions

Our study is the first to provide the AIQR cutoff value for achieving the TIR target value. The range of interstitial glucose variability in AGP was associated with indexes of intra- and interday variations and hyperglycemia. Our results provide new perspectives in the yet-to-be established methods for evaluation of AGP in practical clinical settings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631–40.CrossRef Danne T, Nimri R, Battelino T, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631–40.CrossRef
2.
go back to reference Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42:400–5.CrossRef Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care. 2019;42:400–5.CrossRef
3.
go back to reference Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C. The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemic event: analysis of the DCCT data set. Diabetes Technol Ther. 2019;21:1–5.CrossRef Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C. The association of biochemical hypoglycemia with the subsequent risk of a severe hypoglycemic event: analysis of the DCCT data set. Diabetes Technol Ther. 2019;21:1–5.CrossRef
4.
go back to reference Mazze RS, Lucido D, Langer O, Hartmann K, Rodbard D. Ambulatory glucose profile: representation of verified self-monitored blood glucose data. Diabetes Care. 1987;10:111–7.CrossRef Mazze RS, Lucido D, Langer O, Hartmann K, Rodbard D. Ambulatory glucose profile: representation of verified self-monitored blood glucose data. Diabetes Care. 1987;10:111–7.CrossRef
5.
go back to reference Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl 1):s79–83.PubMed Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes. Diabetes Care. 2004;27(suppl 1):s79–83.PubMed
6.
go back to reference Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41:2275–80.CrossRef Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41:2275–80.CrossRef
7.
go back to reference Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972;8:342–8.CrossRef Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972;8:342–8.CrossRef
8.
go back to reference Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W. Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care. 1997;20:1655–8.CrossRef Kovatchev BP, Cox DJ, Gonder-Frederick LA, Clarke W. Symmetrization of the blood glucose measurement scale and its applications. Diabetes Care. 1997;20:1655–8.CrossRef
9.
go back to reference Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013;15:198–211.CrossRef Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013;15:198–211.CrossRef
10.
go back to reference Beyond A1C Writing Group. Need for regulatory change to incorporate beyond A1C glycemic metrics. Diabetes Care. 2018;41:e92–4.CrossRef Beyond A1C Writing Group. Need for regulatory change to incorporate beyond A1C glycemic metrics. Diabetes Care. 2018;41:e92–4.CrossRef
11.
go back to reference Guo Q, Zang P, Xu S, et al. Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardiovascular autonomic neuropathy independent of HbA1c in Chinese type 2 diabetes. J Diabetes Res 2020; 5817074. Guo Q, Zang P, Xu S, et al. Time in range, as a novel metric of glycemic control, is reversely associated with presence of diabetic cardiovascular autonomic neuropathy independent of HbA1c in Chinese type 2 diabetes. J Diabetes Res 2020; 5817074.
12.
go back to reference Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther. 2019;21:81–5.CrossRef Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther. 2019;21:81–5.CrossRef
13.
go back to reference Matthaei S. Assessing the value of the ambulatory glucose profile in clinical practice. Br J Diab. 2014;14:148–52.CrossRef Matthaei S. Assessing the value of the ambulatory glucose profile in clinical practice. Br J Diab. 2014;14:148–52.CrossRef
14.
go back to reference Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther. 2009;11(Suppl 1):s55–67.CrossRef Rodbard D. Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. Diabetes Technol Ther. 2009;11(Suppl 1):s55–67.CrossRef
15.
go back to reference Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013;7:562–78.CrossRef Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile. J Diabetes Sci Technol. 2013;7:562–78.CrossRef
16.
go back to reference Monnier L, Colette C, Owens DR. The application of simple metrics in the assessment of glycaemic variability. Diabetes Metab. 2018;44:313–9.CrossRef Monnier L, Colette C, Owens DR. The application of simple metrics in the assessment of glycaemic variability. Diabetes Metab. 2018;44:313–9.CrossRef
17.
go back to reference Torimoto K, Okada Y, Hajime M, Kenichi T, Yoshiya T. Risk factors of hypoglycemia in patients with type 2 diabetes mellitus: a study based on continuous glucose monitoring. Diabetes Technol Ther. 2018;20:603–12.CrossRef Torimoto K, Okada Y, Hajime M, Kenichi T, Yoshiya T. Risk factors of hypoglycemia in patients with type 2 diabetes mellitus: a study based on continuous glucose monitoring. Diabetes Technol Ther. 2018;20:603–12.CrossRef
18.
go back to reference Rodbard D. Metrics to evaluate quality of glycemic control: comparison of time in target, hypoglycemic, and hyperglycemic ranges with “risk indices”. Diabetes Technol Ther. 2018;20:325–34.CrossRef Rodbard D. Metrics to evaluate quality of glycemic control: comparison of time in target, hypoglycemic, and hyperglycemic ranges with “risk indices”. Diabetes Technol Ther. 2018;20:325–34.CrossRef
19.
go back to reference Ajjan RA, Cummings MH, Jennings P, et al. Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: implications for clinical practice. Diab Vasc Dis Res. 2018;15(3):175–84.CrossRef Ajjan RA, Cummings MH, Jennings P, et al. Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: implications for clinical practice. Diab Vasc Dis Res. 2018;15(3):175–84.CrossRef
20.
go back to reference Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–603.CrossRef Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–603.CrossRef
Metadata
Title
Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study
Authors
Akemi Tokutsu
Yosuke Okada
Keiichi Torimoto
Yoshiya Tanaka
Publication date
01-12-2020
Publisher
BioMed Central
Keyword
Hypoglycemia
Published in
Diabetology & Metabolic Syndrome / Issue 1/2020
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-020-00577-5

Other articles of this Issue 1/2020

Diabetology & Metabolic Syndrome 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine